Hunan Hansen Pharmaceutical Co., Ltd. (SHE:002412)
China · Delayed Price · Currency is CNY 6.84
+0.08 (1.18%)
At close: Feb 4, 2026
SHE:002412 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 1,050 | 1,004 | 953.95 | 912.38 | 890.33 | 739.97 |
Other Revenue | 0.81 | 0.81 | 1.58 | 3.68 | 1.5 | 1.27 |
| 1,051 | 1,004 | 955.53 | 916.06 | 891.84 | 741.24 | |
Revenue Growth (YoY) | 8.90% | 5.12% | 4.31% | 2.72% | 20.32% | -16.48% |
Cost of Revenue | 247.79 | 250.27 | 262.78 | 267.37 | 256.96 | 227.15 |
Gross Profit | 803.49 | 754.2 | 692.75 | 648.69 | 634.88 | 514.08 |
Selling, General & Admin | 483.58 | 461.5 | 456.53 | 449.58 | 451.63 | 383.83 |
Research & Development | 39.11 | 39.32 | 44.48 | 47.9 | 39.45 | 31.23 |
Other Operating Expenses | 22.3 | 17.15 | 18.56 | 17.95 | 17.94 | 14.32 |
Operating Expenses | 545.89 | 517.87 | 519.55 | 515.46 | 508.75 | 428 |
Operating Income | 257.6 | 236.33 | 173.2 | 133.23 | 126.13 | 86.08 |
Interest Expense | -1.88 | -2.56 | -3.68 | -3.91 | -6.52 | -7.28 |
Interest & Investment Income | 6.46 | 11.27 | 63.12 | 92.49 | 68.59 | 54.94 |
Other Non Operating Income (Expenses) | 0.23 | -0.05 | -12.16 | -0.26 | -0.26 | -0.3 |
EBT Excluding Unusual Items | 262.41 | 244.99 | 220.48 | 221.56 | 187.93 | 133.44 |
Impairment of Goodwill | - | - | - | -38.24 | -39.63 | -25.34 |
Gain (Loss) on Sale of Investments | -53.56 | 2.07 | 1.8 | 1.13 | 0.4 | - |
Gain (Loss) on Sale of Assets | -0.52 | - | -0.02 | - | - | - |
Asset Writedown | -0.16 | -0.17 | -0.27 | -9.28 | -1.33 | -1.67 |
Other Unusual Items | 8.16 | 5.86 | 4.03 | 6.68 | 2.53 | 11.2 |
Pretax Income | 216.32 | 252.76 | 226.02 | 181.85 | 149.9 | 117.63 |
Income Tax Expense | 44.3 | 32.51 | 21 | 14.24 | 15.05 | 11.49 |
Earnings From Continuing Operations | 172.02 | 220.24 | 205.01 | 167.62 | 134.85 | 106.15 |
Net Income | 172.02 | 220.24 | 205.01 | 167.62 | 134.85 | 106.15 |
Net Income to Common | 172.02 | 220.24 | 205.01 | 167.62 | 134.85 | 106.15 |
Net Income Growth | -23.89% | 7.43% | 22.31% | 24.30% | 27.04% | -34.63% |
Shares Outstanding (Basic) | 503 | 503 | 503 | 503 | 503 | 503 |
Shares Outstanding (Diluted) | 503 | 503 | 503 | 503 | 503 | 503 |
Shares Change (YoY) | -0.04% | -0.01% | 0.01% | 0.01% | -0.03% | 0.02% |
EPS (Basic) | 0.34 | 0.44 | 0.41 | 0.33 | 0.27 | 0.21 |
EPS (Diluted) | 0.34 | 0.44 | 0.41 | 0.33 | 0.27 | 0.21 |
EPS Growth | -23.87% | 7.44% | 22.31% | 24.29% | 27.07% | -34.64% |
Free Cash Flow | 135.95 | 119.15 | 141.47 | 132.3 | -16.8 | 34.42 |
Free Cash Flow Per Share | 0.27 | 0.24 | 0.28 | 0.26 | -0.03 | 0.07 |
Dividend Per Share | - | - | - | 0.300 | - | - |
Gross Margin | 76.43% | 75.08% | 72.50% | 70.81% | 71.19% | 69.36% |
Operating Margin | 24.50% | 23.53% | 18.13% | 14.54% | 14.14% | 11.61% |
Profit Margin | 16.36% | 21.93% | 21.46% | 18.30% | 15.12% | 14.32% |
Free Cash Flow Margin | 12.93% | 11.86% | 14.80% | 14.44% | -1.88% | 4.64% |
EBITDA | 290.11 | 276.74 | 224.17 | 184.82 | 177.31 | 136.12 |
EBITDA Margin | 27.59% | 27.55% | 23.46% | 20.18% | 19.88% | 18.36% |
D&A For EBITDA | 32.5 | 40.42 | 50.97 | 51.59 | 51.19 | 50.04 |
EBIT | 257.6 | 236.33 | 173.2 | 133.23 | 126.13 | 86.08 |
EBIT Margin | 24.50% | 23.53% | 18.13% | 14.54% | 14.14% | 11.61% |
Effective Tax Rate | 20.48% | 12.86% | 9.29% | 7.83% | 10.04% | 9.76% |
Revenue as Reported | 1,051 | 1,004 | 955.53 | 916.06 | 891.84 | 741.24 |
Advertising Expenses | - | 103.22 | 136.1 | 111.88 | 92.25 | 79.59 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.